Peter A. Thompson - 17 Jun 2026 Form 4 Insider Report for Sionna Therapeutics, Inc. (SION)

Reporting relationship: Director
Issuer ticker: SION
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 17:45:51 UTC
Prior SEC filing: 15 Jun 2026
Next SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: By: Jennifer Fitzpatrick, Attorney-in-Fact For: Peter Thompson

Key filing fact

Peter A. Thompson filed Form 4 for Sionna Therapeutics, Inc. (SION) on 18 Jun 2026.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for Sionna Therapeutics, Inc. (SION).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 17:45.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001357522 Primary reporting owner

Thompson Peter A.

Relationship: Director
Address: C/O SIONNA THERAPEUTICS, INC., 21 HICKORY DRIVE, SUITE 500, WALTHAM
Signature: By: Jennifer Fitzpatrick, Attorney-in-Fact For: Peter Thompson
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SION transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +17,340
Change %
Price: $0.000000^*
Shares after: 17,340
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,340
Exercise price: $36.73
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.

Footnote F2

This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.